Novel treatments for mantle cell lymphoma
BTK inhibitors have seen success in treating various hematological malignancies, and their approval has been extended to mantle cell lymphoma (MCL). Here, Simon Rule, MD, from Plymouth University, Ply...
Author: VJHemOnc
Added: 07/24/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 24, 2018 Category: Cancer & Oncology Source Type: podcasts
Novel BTK inhibitors for Waldenstrms macroglobulinemia
Ramon Garcia-Sanz, MD, PhD from the University Hospital of Salamanca, Salamanca, Spain, shares exciting data in Waldenstrms macroglobulinemia (WM) from the 23rd congress of European Hematology Assoc...
Author: VJHemOnc
Added: 07/24/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 24, 2018 Category: Cancer & Oncology Source Type: podcasts
Advances in predictive biomarkers for immuno-oncology agents
Newer treatments for hematological malignancies, including immunotherapies and cellular therapies, are more targeted than historical chemotherapies. This means that the presence of the specific target...
Author: VJHemOnc
Added: 07/24/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 24, 2018 Category: Cancer & Oncology Source Type: podcasts
Bringing MRD measurement to the clinic
The measurement and use of minimal residual disease (MRD) is an exciting development in the world of hematological oncology. So, what is MRD, how can it be measured, why is it important, and how can i...
Author: VJHemOnc
Added: 07/24/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 24, 2018 Category: Cancer & Oncology Source Type: podcasts
CAR T-cells in ALL: an overview
CAR T-cells are gaining traction as a therapy for a variety of hematological malignancies. Here, Oliver Ottmann, MD, FRCPath, of Cardiff University, Cardiff, UK, discusses their role in acute lymphobl...
Author: VJHemOnc
Added: 07/24/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 24, 2018 Category: Cancer & Oncology Source Type: podcasts
